Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio Sells 4,380 Shares

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Bioventus Stock Performance

BVS stock traded down $0.37 during midday trading on Thursday, reaching $9.95. 322,403 shares of the company’s stock traded hands, compared to its average volume of 272,552. The company has a 50-day moving average price of $10.37 and a two-hundred day moving average price of $10.83. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38. The firm has a market capitalization of $807.44 million, a PE ratio of -16.31 and a beta of 0.85.

Institutional Investors Weigh In On Bioventus

A number of hedge funds and other institutional investors have recently bought and sold shares of BVS. Tower Research Capital LLC TRC raised its holdings in Bioventus by 106.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after acquiring an additional 1,786 shares during the period. Plato Investment Management Ltd bought a new stake in Bioventus during the 4th quarter valued at $38,000. Virtus Fund Advisers LLC bought a new stake in Bioventus during the 3rd quarter valued at $42,000. Quest Partners LLC bought a new stake in Bioventus during the 3rd quarter valued at $51,000. Finally, Quarry LP bought a new stake in Bioventus during the 3rd quarter valued at $59,000. Institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

BVS has been the topic of several research analyst reports. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group upped their price objective on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.